Lin Kyaw

Lin Kyaw

Auto-generated profile, based on publicly available information

Lin Kyaw

Department of Urology, National University Hospital, National University Health System, Singapore

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
LKLin Kyaw
Lin Kyaw
NLNai Ming Lai
Nai Ming Lai
SIShridhar Ganpati Iyer
Shridhar Ganpati Iyer
DLDale Ser Kheng Lincoln Loh
Dale Ser Kheng Lincoln Loh
SLStanley Eu Kuang Loh
Stanley Eu Kuang Loh
VMVidyadhar P. Mali
Vidyadhar P. Mali

7 August 2024 in Prostate International
Verified
Journal Article
Open access
LKLin Kyaw
Lin Kyaw
QLQi Yang Lim
Qi Yang Lim
YLYu Xi Terence Law
Yu Xi Terence Law
COChloe Shu Hui Ong
Chloe Shu Hui Ong
WLWei Tim Loke
Wei Tim Loke
HTHo Yee Tiong
Ho Yee Tiong
Introduction: Prostate cancer is now one of the most prevalent cancers in men in Asia. As the average life expectancy of Asian males with prostate cancer increases with the availability of treatment options, the possible risk of cardiac-related adverse effects arising from androgen-receptor targeted agents (ARTA) may be increased due to the greater exposure. We aim to perform a meta-analysis on the incidence of cardiac-related adverse events in Asian patients with prostate cancer treated with ARTA. Methods: Databases were thoroughly searched for relevant articles. The PICOS model was used to frame our clinical question, and 2 independent authors went through several rounds of screening to select the final included studies. Meta-analysis was done using the Cochran-Mantel-Haenszel method. Quality assessment was carried out with the Cochrane Risk of Bias tool RoB 2. Results: 7 randomized controlled trials were included for the final meta-analysis. Use of ARTA in Asian men did not show any significant increase in the total number of cardiac-related adverse events (RR: 1.66 [0.84-3.26], p=0.14). However, there was increase in incidence of hypertension (RR: 2.30 [1.41-3.73], p=0.0008) and hypertension crises (RR 16.87 [2.13-133.34], p=0.007). Subgroup analysis of the type of ARTA used showed enzalutamide having the highest risk of hypertension (RR: 5.86 [2.10-16.38], p=0.0008). Conclusion: Although ARTA did not show any significant increase in incidence of cardiac-related adverse events, there is an increased risk of hypertension especially with the use of enzalutamide. With this knowledge, closer blood pressure monitoring is needed for patients started on ARTA, especially enzalutamide.